Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965479 | 1.00 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL15566279 | 0.86 | TSHR (0.45) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL29746616 | 0.85 | RAPGEF4 (0.48) | KDM4EHSD17B10TP53TSHRL3MBTL1 | |
| SCHEMBL29287216 | 0.82 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL21240854 | 0.82 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL15232029 | 0.82 | MAPK11 (0.48) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL21462778 | 0.82 | PLAU (0.46) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL16056406 | 0.79 | MCL1 (0.42) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL21274660 | 0.79 | OXER1 (0.42) | KDM4EHSD17B10ALDH1A1HPGDTP53 | |
| SCHEMBL1752188 | 0.79 | MAPK11 (0.57) | KDM4EHSD17B10ALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612520-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | Il Dong Pharmaceutical Co., Ltd. (KR) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018190643-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-18 | — | — | WO | disclosed |
| CN-108440370-A | Inhibitors of viral replication | 鲁汶天主教大学 | 2018-08-24 | — | — | CN | disclosed |
| CN-104024223-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2018-07-24 | — | — | CN | disclosed |
| EP-2820009-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130976-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | KDM4E 3583/4885HSD17B10 2943/4885ALDH1A1 2271/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | KDM4E 3894/4885HSD17B10 2212/4885ALDH1A1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.